Loading clinical trials...
Loading clinical trials...
Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes
The purpose of this study is to determine the short-term effects of the antimalarial medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled intravenous glucose tolerance testing (FSIGTT) methodology to study changes in insulin secretion and glucose tolerance in subjects at risk for developing Type 2 diabetes.
Diabetes is approaching epidemic proportions in the United States. This study evaluates the mechanisms of action of a generic drug that may have effects on glucose metabolism.
Age
18 - 85 years
Sex
ALL
Healthy Volunteers
No
University of Pittsburgh, Montefiore Hospital
Pittsburgh, Pennsylvania, United States
Start Date
March 1, 2011
Primary Completion Date
March 1, 2013
Completion Date
December 1, 2014
Last Updated
February 26, 2016
32
ACTUAL participants
hydroxychloroquine
DRUG
Placebo
OTHER
Lead Sponsor
University of Pittsburgh
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05041491